This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MarketVIEW: Japanese Encephalitis Vaccines

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

MarketVIEW: Japanese encephalitis vaccines

Japanese encephalitis (JE) is an enzootic mosquito-borne viral disease where humans are incidental "dead end" hosts. JE currently affects countries of SE Asia and Western Pacific where around 3 billion people are considered at risk. The disease mainly affects children (< 15yrs) in poor rural areas where it can result in 25% mortality (est 10,000 deaths/yr) or residual neuropsychiatric sequelae (30% of cases). There are no specific treatments for JE. 

This MarketVIEW product is comprised of a comprehensive MS Excel-based model(s) + Summary executive presentation which forecast the potential commercial value of Japanese Encephalitis vaccine(s) across endemic and markets to 2030. The model(s) contain value ($ m) and volume (mio doses) predictions for endemic countries in all age segments in both the public and private sector down to vaccine type. LO, BASE & HI forecast scenarios model expected demand from newly adopting countries as postulated by the PATH JE project. 


Contents – Summary presentation (MS PowerPoint based)ContentsAuthors noteExecutive summaryCommercial model: key outputsJE vaccine: available market (endemic/public) ($ 000s) – all children to 2030JE vaccine: available market (endemic/public) ($ 000s) – infants to 2030JE vaccine: available market (endemic/public) ($ 000s) – 1 to 15 yrs to 2030JE vaccine: endemic segment volume analysis (mio doses/yr)JE vaccine: available market (endemic/private) ($ 000s) – 1 to 15 yrs to 2030JE vaccine: market by vaccine type 2015JE vaccines: all market segments, revenues/yr (2015)JE: disease backgroundJE: transmission cycleJE: geographic distributionJE: epidemiologyJE: genotype distributionJE: country reporting/surveillanceJE: WHO reported cases 2006 - 2010JE: disease profile of main endemic countriesRisk of JE by country, region and seasonDALYs per 100,000 persons in JE endemic countriesJE: disease trends and dynamicsJE: factors contributing to increasing transmissionJE and travelersJE: control and preventionJE control: aligned with major stakeholder objectivesPATH JE project: strategic goalsJE vaccines: policy evolutionJE vaccines: immunological aspectsImpact of JE vaccinationJE vaccination and cost effectivenessCurrently licensed JE vaccines (endemic)Country status of JE control through immunizationCountry use of JE vaccine types: SEA regionCountry use of JE vaccine types: WPR regionIndia: cases and deaths 1993 – 2009India – JE priority districtsIndia – mass vaccination campaignsIndia – mass vaccination campaigns: progress to dateTransition to new JE vaccinesAvailability of new JE vaccinesJE vaccination: country future planning – SEA regionJE vaccination: country future planning – WPR regionCommercial model: detailed assumptions per WHO region/countryJE vaccine demand forecast: countries modelledJE vaccines: modelling strategyCommercial model assumptions – SEA regionCommercial model assumptions – WPR regionPricing case studies for endemic vaccinesJE vaccine prices used in modelSource materialJE vaccines (PATH): estimated implementation 2006 – 2015Timeline of JE in Thailand 1971 – 2006Japan: immunization schedule 2011 (< 20 yrs) Japan: JEV vaccinations given 1995 – 2009 (000s)Ensebakku subcutaneous JE vaccine: History of developmentIxiaro/JESPECT – distribution structureBibliographyAbout VacZine AnalyticsDisclaimerBack pagePAGES: 81 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model (MS Excel-based) – endemic markets (public/private)Title sheetCHARTS – VAL (private)CHARTS – VAL (pub)CHARTS – VOL (pub)GRAND VALUE SUMMARYValue by vaccine typeValue Summary (pub <1 yrs)>Value Summary (pub 1-15 yrs)Value Summary (priv 0 - 15 yrs)Global price summaryVolume Summary (pub <1 yrs)>Volume Summary (pub 1-15 yrs)Volume Summary (priv 0 - 15 yrs)Volume SummariesSEA regionBangladesh (pub) Bangladesh (priv) Bhutan (pub) Bhutan (priv) India (pub) India (priv) Indonesia (pub)

Indonesia (priv)

Korean DPR (pub)

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,838.48 +26.29 0.15%
S&P 500 2,090.79 +1.65 0.08%
NASDAQ 5,118.5140 +15.7060 0.31%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs